Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ricky W Johnstone

Showing results (21-30 of 188) with videos related to

Pageof 19
Sort By:
Oncoimmunology|April 5, 2014
The anticancer effects of HDAC inhibitors require the immune systemAlison C West, Mark J Smyth, Ricky W Johnstone
Cell|February 8, 2002
Apoptosis: a link between cancer genetics and chemotherapyRicky W Johnstone, Astrid A Ruefli, Scott W Lowe
Expert Opinion on Investigational Drugs|April 28, 2007
Histone deacetylase inhibitors in cancer therapyWalid K Rasheed, Ricky W Johnstone, H Miles Prince
Cancer Letters|April 11, 2009
Enhancing the apoptotic and therapeutic effects of HDAC inhibitorsAilsa J Frew, Ricky W Johnstone, Jessica E Bolden
Future Oncology (London, England)|June 13, 2009
Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumorsH Miles Prince, Mark J Bishton, Ricky W Johnstone
Current Opinion in Hematology|May 10, 2014
Rational combination therapies targeting survival signaling in aggressive B-cell leukemia/lymphomaMichaela Waibel, Gareth Gregory, Jake Shortt, et al.
JAK-STAT|August 12, 2016
Constitutive IFNα/β signaling maintains expression of signaling intermediaries for efficient cytokine responsesNicole L Messina, Christopher J P Clarke, Ricky W Johnstone
Expert Review of Anticancer Therapy|March 28, 2008
Histone deacetylase inhibitors in lymphoma and solid malignanciesWalid Rasheed, Mark Bishton, Ricky W Johnstone, et al.
The FEBS Journal|April 27, 2016
How do tumor cells respond to HDAC inhibition?Andrea Newbold, Katrina J Falkenberg, H Miles Prince, et al.
Nature Reviews. Cancer|February 24, 2017
A chemical probe toolbox for dissecting the cancer epigenomeJake Shortt, Christopher J Ott, Ricky W Johnstone, et al.
Pageof 19

Showing results (21-30 of 188) with videos related to

Sort By:
Pageof 19
Oncoimmunology|April 5, 2014
The anticancer effects of HDAC inhibitors require the immune systemAlison C West, Mark J Smyth, Ricky W Johnstone
Cell|February 8, 2002
Apoptosis: a link between cancer genetics and chemotherapyRicky W Johnstone, Astrid A Ruefli, Scott W Lowe
Expert Opinion on Investigational Drugs|April 28, 2007
Histone deacetylase inhibitors in cancer therapyWalid K Rasheed, Ricky W Johnstone, H Miles Prince
Cancer Letters|April 11, 2009
Enhancing the apoptotic and therapeutic effects of HDAC inhibitorsAilsa J Frew, Ricky W Johnstone, Jessica E Bolden
Future Oncology (London, England)|June 13, 2009
Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumorsH Miles Prince, Mark J Bishton, Ricky W Johnstone
Current Opinion in Hematology|May 10, 2014
Rational combination therapies targeting survival signaling in aggressive B-cell leukemia/lymphomaMichaela Waibel, Gareth Gregory, Jake Shortt, et al.
JAK-STAT|August 12, 2016
Constitutive IFNα/β signaling maintains expression of signaling intermediaries for efficient cytokine responsesNicole L Messina, Christopher J P Clarke, Ricky W Johnstone
Expert Review of Anticancer Therapy|March 28, 2008
Histone deacetylase inhibitors in lymphoma and solid malignanciesWalid Rasheed, Mark Bishton, Ricky W Johnstone, et al.
The FEBS Journal|April 27, 2016
How do tumor cells respond to HDAC inhibition?Andrea Newbold, Katrina J Falkenberg, H Miles Prince, et al.
Nature Reviews. Cancer|February 24, 2017
A chemical probe toolbox for dissecting the cancer epigenomeJake Shortt, Christopher J Ott, Ricky W Johnstone, et al.
Pageof 19